glp-1 wegovy Novo Nordisk launches weight-loss pill in US, triggering price war | Pharmaceuticals industry GLP-1 nonresponders: Up to 1

While these medications offer potential healthcare savings by reducing obesity-related conditions, their high cost (approximately $1,000 per month in the US) poses significant challenges for healthcare budgets and raises questions about cost-effectiveness and equitable access

In rare cases, this can increase the risk of regurgitation and aspirationstomach contents going into the lungswhich can lead to pneumonia, prolonged hospital stay, or even intensive care

Direct head-to-head comparisons have not been done

Open 17 , 100236 (2023) K.S

Transcriptional activation of the proglucagon gene by lithium and beta-catenin in intestinal endocrine L cells